SOUTH SAN FRANCISCO, Calif. -- Richard DeLateur has joined Fluidigm Corporation as Chief Financial Officer. Mr. DeLateur has 25 years of finance, general management, and business development experience, including 20 years at Intel Corporation (NYSE:INTC). His most recent position at Intel was General
"Rich has the background in manufacturing, early stage companies, and strategic alliances that will help push Fluidigm to a new level of excellence," said Gajus Worthington, Fluidigm's CEO. "I couldn't name another individual who would be a better fit for this company."
"It's a rare opportunity to be involved with a company on the cutting edge of a technology that has such widespread implications for everyday life," said Richard DeLateur, Fluidigm's CFO. "I am honored to be part of a team as dedicated and capable as Fluidigm's employees."
The impact of Fluidigm's technology on life sciences may well parallel that of Intel's on the electronics industry, given the similarities in form and function of Fluidigm's integrated fluidic circuits (IFCs) and Intel's products. IFCs are networks fabricated of elastomer, using processes originating in the semiconductor industry. IFCs miniaturize and integrate a variety of functional elements on a chip to provide radical improvements in efficiencies. However, rather than electrons, the inputs to Fluidigm's chips are biological samples and reagents used for life sciences and allied fields.
After his departure from Intel, Rich joined Topspin Communications as Chief Financial Officer. Topspin Communications at the time was a venture-capital funded private company producing innovative server interconnect and virtualization technology. Topspin was acquired by Cisco Systems in May 2005.
Rich holds a B.A. in Economics from the University of California, Davis. Rich was awarded his Chartered Financial Analyst (CFA) certification in 1999.
About Fluidigm
Fluidigm develops and distributes systems for analysis and synthesis of biomolecules in nano- and pico-volume environments. The company's vision is to create and to lead a new industry in which efficiencies inconceivable today are achieved through the advent of integrated fluidic circuits (IFCs). In 2003 the Company introduced the TOPAZ(R) System, which streamlines the process of protein crystallization, an essential capability for rational drug design. Currently, the Company is rolling out the BioMark(TM) System, which includes the dynamic array IFC, for ultra high-throughput real-time RT-PCR. Under development is an IFC that isolates and detects a target sequence in a high background of similar sequences and an IFC that miniaturizes and integrates the steps involved with immunoassays. Based in South San Francisco, California, the Company is privately held and backed by premier investors: Versant Ventures, Euclid SR Partners, InterWest Partners, Lehman Brothers Healthcare Fund, Bruce Burrows, the Singapore EDB, Lilly BioVentures, the Invus Group, GE Equity, SightLine Partners, and Alloy Ventures.